La maladie de Parkinson au Canada (serveur d'exploration) - Exploration (Accueil)

Index « Mesh.i » - entrée « Clinical Trials as Topic »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Clinical Protocols < Clinical Trials as Topic < Clinical Trials, Phase I as Topic  Facettes :

List of bibliographic references indexed by Clinical Trials as Topic

Number of relevant bibliographic references: 45.
[0-20] [0 - 20][0 - 45][20-40]
Ident.Authors (with country if any)Title
000544 (2015) Soania Mathur [Canada] ; Steve Dewitte [Royaume-Uni] ; Israel Robledo [Royaume-Uni] ; Tom Isaacs [Royaume-Uni] ; Jon Stamford [Royaume-Uni]Rising to the Challenges of Clinical Trial Improvement in Parkinson's Disease.
000559 (2015) Marina Picillo [Italie] ; Nancy Kou [Canada] ; Paolo Barone [Italie] ; Alfonso Fasano [Canada]Recruitment strategies and patient selection in clinical trials for Parkinson's disease: Going viral and keeping science and ethics at the highest standards.
000603 (2015) Ronald B. Postuma ; Jean-Francois Gagnon ; Josie-Anne Bertrand ; Daphné Génier Marchand ; Jacques Y. MontplaisirParkinson risk in idiopathic REM sleep behavior disorder
000608 (2015) Marie-Laure Welter [France] ; David Grabli [France] ; Carine Karachi [France] ; Nicolas Jodoin [France] ; Sara Fernandez-Vidal [France] ; Yohann Brun [France] ; Soledad Navarro [France] ; Alister Rogers [France] ; Philippe Cornu [France] ; Bernard Pidoux [France] ; Jérôme Yelnik [France] ; Emmanuel Roze [France] ; Eric Bardinet [France] ; Marie Vidailhet [France]Pallidal activity in myoclonus dystonia correlates with motor signs.
000654 (2015) Shraddha Chakradhar [États-Unis]Many returns: call-ins and breakfasts hand back results to study volunteers.
000751 (2015) Fang Ba [Canada] ; W R Wayne Martin [Canada]Dopamine transporter imaging as a diagnostic tool for parkinsonism and related disorders in clinical practice.
000764 (2015) Lorraine V. Kalia [Canada] ; Suneil K. Kalia [Canada] ; Anthony E. Lang [Canada]Disease-modifying strategies for Parkinson's disease.
000887 (2014) Jamie Eberling [États-Unis] ; Lona Vincent [États-Unis] ; Jennifer G. Goldman ; Daniel Weintraub ; Jaime Kulisevsky ; Connie Marras ; Glenn Stebbins ; Karl KieburtzTherapeutic Development Paths for Cognitive Impairment in Parkinson's Disease: Report of a Regulatory Roundtable
000890 (2014) Leonardo Cortez ; Valerie SimThe therapeutic potential of chemical chaperones in protein folding diseases
000922 (2014) Tiago A. Mestre [Canada] ; Alberto J. Espay ; Connie Marras ; Mark H. Eckman ; Pierre Pollak ; Anthony E. LangSubthalamic nucleus-deep brain stimulation for early motor complications in Parkinson's disease-the EARLYSTIM trial: early is not always better.
000937 (2014) Donald A. Mcafee [Canada] ; Jonathan Hadgraft [Royaume-Uni] ; Majella E. Lane [Royaume-Uni]Rotigotine: the first new chemical entity for transdermal drug delivery.
000F10 (2013) Anthony E. Lang [Canada] ; Eldad Melamed [Israël] ; Werner Poewe [Autriche] ; Olivier Rascol [France]Trial designs used to study neuroprotective therapy in Parkinson's disease
001142 (2012) Sheridan M. Hoy [Nouvelle-Zélande] ; Gillian M. KeatingRasagiline: a review of its use in the treatment of idiopathic Parkinson's disease.
001621 (2011) M Anne Harris [Canada] ; Mieke Koehoorn ; Kay TeschkeOngoing challenges to finding people with Parkinson's disease for epidemiological studies: a comparison of population-level case ascertainment methods.
001632 (2011) Marco Onofrj [Italie] ; Astrid ThomasMovement disorders in focus: experts debate on pathophysiology and concomitant signs.
001811 (2011) Connie Marras [Canada] ; Michael P. Mcdermott [États-Unis] ; Ken Marek [États-Unis] ; Paula Rochon [Canada] ; Gary Naglie [Canada] ; Caroline M. Tanner [États-Unis] ; Alice Rudolph [États-Unis] ; Ira Shoulson [États-Unis] ; Anthony E. Lang [Canada]Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts
001898 (2011) Anthony E. Lang [Canada]A critical appraisal of the premotor symptoms of Parkinson's disease: Potential usefulness in early diagnosis and design of neuroprotective trials
001980 (2010) Raúl De La Fuente-Fernández [Canada] ; Michael Schulzer ; Edwin Mak ; Vesna SossiTrials of neuroprotective therapies for Parkinson's disease: problems and limitations.
001A52 (2010) Sarah C. Lidstone [Canada] ; Michael Schulzer ; Katherine Dinelle ; Edwin Mak ; Vesna Sossi ; Thomas J. Ruth ; Raul De La Fuente-Fernández ; Anthony G. Phillips ; A Jon StoesslEffects of expectation on placebo-induced dopamine release in Parkinson disease.
001A84 (2010) Michael G. Schlossmacher [Canada] ; Brit MollenhauerBiomarker research in Parkinson's disease: objective measures needed for patient stratification in future cause-directed trials.
001F84 (2009) Jonathan Kimmelman [Canada] ; Alex John London [États-Unis] ; Bernard Ravina [États-Unis] ; Tim Ramsay [Canada] ; Mark Bernstein [Canada] ; Alan Fine [Canada] ; Frank W. Stahnisch [Canada] ; Marina Elena Emborg [États-Unis]Launching invasive, first‐in‐human trials against Parkinson's disease: Ethical considerations

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Mesh.i -k "Clinical Trials as Topic" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Mesh.i  \
                -Sk "Clinical Trials as Topic" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    Mesh.i
   |clé=    Clinical Trials as Topic
}}

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022